Kyntra Bio Inc (KYNB) Institutional Buying & Selling Tracker (Q2 2026)

KYNB ranks #7638 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

28 institutions disclose a position in KYNB, but none treat it as a major bet — even Birchview Capital, LP, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

KYNB posted net income of $183.2M over the trailing twelve months, and currently trades at a P/E of 0.1.

• Profitable — net income of $183.2M over the trailing twelve months
• Revenue grew 103.9% year over year
• Net income improved year over year, from -$2.1M to $183.2M
• Operating cash flow was negative, using $4.8M in cash
• Current ratio of 3.39x — enough short-term assets to cover short-term liabilities